Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases

Celltrion will develop and commercialize Kaigene's nonclinical-stage antibody assets, KG006 and KG002, under an exclusive licensing agreement. Kaigene will receive $8M upfront payment and up to $736M in potential milestone payments, including $11M in near-term milestones through the...